A Study of Guselkumab in Pediatric Participants With Moderately to Severely Active Crohn's Disease

Inclusion Criteria:

• Participants must have a diagnosis of Crohn's Disease (CD) or fistulizing CD, withactive colitis, ileitis, or ileocolitis, confirmed at any time in the past byclinical, endoscopic, and histologic criteria.

• Participants must have moderately to severely active CD (as defined by a baselinePediatric Crohn's Disease Activity Index [PCDAI] score greater than or equal to [>=]

• Participants must have endoscopy with evidence of active CD defined as SimpleEndoscopic Score for Crohn's Disease (SES-CD) score greater than or equal to (>=) 6 (or >=4 for participants with isolated ileal disease) within 1 month of receivingstudy intervention at Week 0

• Participants must have a prior or current CD medication history that includes eitherinadequate response, loss of response to or failure to tolerate current treatmentimmunomodulators or with oral or intravenously (IV) corticosteroids or have receivedbiologic therapy/JAK inhibitor for the treatment of CD and have a documented historyof inadequate response, loss of response (LOR), or intolerance to the biologictherapy/JAK inhibitor

Exclusion Criteria:

• Participants has complications of CD such as symptomatic strictures or stenosis,short gut syndrome, or any other manifestation that might be anticipated to requiresurgery.

• Participants must not have an abscess

• Participants must not have any kind of bowel resection within 26 weeks or any otherintra-abdominal surgery within 12 weeks of baseline